Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia

  • Jason Powell
    Address correspondence to: Jason Powell, PharmD, BCACP, Department of Pharmacotherapy and Translational Research, Colleges of Pharmacy and Medicine, University of Florida, 410 NE Waldo Road, Gainesville, FL 32641, USA.
    Department of Pharmacotherapy and Translational Research, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL, USA
    Search for articles by this author
  • Chris Piszczatoski
    Department of Pharmacotherapy and Translational Research, and the Department of Community Health and Family Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL, USA
    Search for articles by this author



      This article discusses the pharmacology of bempedoic acid, the trials that led to United States Food and Drug Administration (FDA) approval of its use, and the overall safety and efficacy of this therapy in heterozygous familial hypercholesterolemia, established atherosclerotic cardiovascular disease (ASCVD), and hyperlipidemia.


      A database search of PubMed and was conducted for articles published between January 2012 to September 2020 and containing the key words bempedoic acid, ezetimibe, Nexletol and Nexlizet. Trials from the CLEAR series were selected, as they played a pivotal role in the establishment of FDA approval, along with additional trials published after FDA approval, which provided novel evidence on the use of bempedoic acid in the treatment of hypercholesterolemia. Publications that were not randomized, controlled trials were not included in this review. Only randomized controlled trials in which ezetimibe was used in conjunction with bempedoic acid were included in this review as they were relevant to the new FDA approval of bempedoic acid.


      The findings of the present review show that bempedoic acid is both an effective and well-tolerated option for the treatment of hypercholesterolemia when used without ezetimibe in addition to standard therapy. It also appears that the combination with ezetimibe increases the cholesterol-lowering effect more than either agent alone when added to standard therapy.


      Hypercholesteremia continues to be a major contributing factor leading to ASCVD. Bempedoic acid is an additional treatment option, along with both statins and diet and exercise, for reducing cholesterol levels and ASCVD events. With the new FDA approval, bempedoic acid may offer an effective therapy for reducing low-density lipoprotein cholesterol in patients at high risk for cardiovascular events due to established ASCVD or heterozygous familial hypercholesterolemia.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Grundy S.M.
        • Stone M.J.
        • Bailey A.L.
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines.
        J Am Coll Cardiol. 2019; 73: e285-e350
        • Sjouke B.
        • Kusters D.M.
        • Kindt I.
        • et al.
        Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
        Eur Heart J. 2015; 36: 560-565
        • Boekholdt S.M.
        • Hovingh G.K.
        • Mora S.
        • et al.
        Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
        J Am Coll Cardiol. 2014; 64: 485-494
      1. Nexletol (Bempedoic Acid) [prescribing Information]. Piramal Healthcare UK, Northumberland, UK2020
      2. Nexlizet (Bempedoic Acid and Ezetimibe) [prescribing Information]. Piramal Health care UK, Northumberland, UK2020
      3. Zetia (Ezetimibe) [prescribing Information]. MSD International GmbH, Luzern, Switzerland2013
        • Ray K.K.
        • Bays H.E.
        • Catapano A.L.
        • et al.
        Safety and efficacy of bempedoic acid to reduce LDL cholesterol.
        N Engl J Med. 2019; 380: 1022-1032
        • Goldberg A.C.
        • Leiter L.A.
        • Stroes E.S.G.
        • et al.
        Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial.
        JAMA. 2019; 322: 1780-1788
        • Laufs U.
        • Banach M.
        • Mancini J.
        • et al.
        Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.
        J Am Heart Assoc. 2019; 8e011662
        • Ballantyne C.
        • Banach M.
        • Mancini R.
        • et al.
        Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.
        Atherosclerosis. 2018; 277: 195-203
        • Ballantyne C.
        • Laufs U.
        • Ray K.K.
        • et al.
        Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
        Eur J Prev Cardiol. 2020; 27: 593-603
      4. Nexletol [GoodRx website].
        (Available at:)
        Date: 2020
        Date accessed: April 15, 2020
      5. Nexletol access [Esperion website].
        (Available from:)
        Date: 2020
        Date accessed: April 15, 2020
        • Gagné C.
        • Bays H.E.
        • Weiss S.R.
        • et al.
        Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
        Am J Cardiol. 2002; 90: 1084-1091
        • Thompson P.
        • MacDougall D.
        • Newton R.
        • et al.
        Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
        J Clin Lipidol. 2016; 10: 556-567
      6. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy [ website].
        (Available at:)
      7. Alirocumab [GoodRx website].
        (Available from:)
        Date: 2020
        Date accessed: May 30, 2020
        • Perera K.
        • Kam N.
        • Ademi Z.
        • et al.
        Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: a cost-effectiveness analysis.
        J Clin Lipidol. 2020; S1933–2874: 30259-30262
      8. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo [ website].
        (Available at:)
        • Asbeutah A.A.A.
        • Asbeutah S.A.
        • Abu-Assi M.A.
        A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with bempedoic acid.
        Am J Cardiol. 2020; 132: 166-168
      9. Bempedoic acid + ezetimibe fixed-dose combination (FDC) study in patients with type 2 diabetes and elevated LDL-C [ website].
        (Available at:)
        • Morris A.A.
        • Ko Y.A.
        • Hutcheson S.H.
        • Quyyumi A.
        Race/ethnic and sex differences in the association of atherosclerotic cardiovascular disease risk and healthy lifestyle behaviors.
        J Am Heart Assoc. 2018; 7e008250